腹腔镜术后辅助GnRHa治疗子宫肌瘤的疗效观察

目的观察评价腹腔镜术后辅助GnRHa治疗子宫肌瘤的疗效。方法选取2010年1月～2014年6月在我院妇科确诊收治且行腹腔镜切除术的子宫肌瘤患者60例为研究对象。随机分为观察组与对照组，各30例。对照组采用常规腹腔镜治疗；观察组在对照组基础上术后辅助应用GnRHa治疗。结果两组治疗前子宫体积比较，差异无统计学意义（P〉0．05）；术后6个月观察组子宫体积小于对照组，差异有统计学意义（P〈0．05）。治疗前两组血红蛋白平均水平比较，差异无统计学意义（P〉0．05）；术后6个月观察组水平显著高于对照组，差异有统计学意义（P〈0．05）。术后随访12个月，观察组术后复发2例，复发率为6．7％，对照组复发10例，复发率为33.3％，差异有统计学意义（P〈0．05）。结论在腹腔镜切除子宫肌瘤术后辅助应用GnRHa，可有效缩小子宫体积，降低术后复发率，为术后预防复发开辟了新途径，更为患者选择子宫肌瘤切除术提供了较多保障，在提高患者的生活质量方面具有重要意义。

Objective To observe and evaluate the clinical effect of GnRHa in the treatment of uterine myoma after laparoscopic operation. Methods From January 2014 to June 2010 in our hospital, 60 cases of uterine fibroids were treated with laparoscopic resection of uterine fibroids. 60 cases were randomly divided into observation group and control group, 30 cases in each group, the observation group was treated with GnRHa therapy. Results There was no significant difference between the two groups before treatment （P〉0.05）; 6 months after operation, the uterine volume was less than the control group, the difference was statistically significant （P〈0.05）. The average level of hemoglobin in the first two groups was similar （P〉0.05）; the level of the observation group was significantly higher than that in the control group at 6 months after operation, and the difference was statistically significant （P〈0.05）. The two groups of patients were followed up for 12 months was observed in groups of postoperative recurrence in 2 cases, the recurrence rate was 6.7%, 10 cases of control group, the recurrence, the recurrence rate was 33.3%, group compared with the control group were higher than those in the observation group, and the difference is significant （P〈0.05）. Conclusion Laparoscopic resection of uterine leiomyoma surgery adjuvant application of GnRHa, can effectively reduce the volume of the uterus, reduce postoperative recurrence rate, postoperative relapse prevention opens up a new way, patients choose uterine fibroids resection provides more security in it is important to improve the patients quality of life mask.